A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira in Patients With Moderate to Severe Active Rheumatoid Arthritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms ADMYRA
- Sponsors HEXAL; Sandoz
- 07 Jun 2017 Biomarkers information updated
- 16 Jan 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jan 2017.
- 03 Nov 2016 Status changed from recruiting to active, no longer recruiting.